{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7","value":"0.75"},{"groupId":"OG002","spread":"1.5","value":"1.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"The maximum concentration ratio between Day -7 collections to Day 2 collections. Collection time points are baseline, 30 and 55 minutes after the start of M6620 infusion, 5, 15, 30 minutes, 1, 2, 4, 23 (Day 3), 48 (Day 4), and 72 hours (Day 5) after the end of M6620 infusion given on Day 2.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received M6620 (VX-970, berzosertib) 120 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.","id":"OG000","title":"Dose Level 1"},{"description":"Patients received M6620 (VX-970, berzosertib) 160 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.","id":"OG001","title":"Dose Level 2"},{"description":"Patients received M6620 (VX-970, berzosertib) 200 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.","id":"OG002","title":"Dose Level 3"}],"paramType":"MEAN","populationDescription":"Based on samples collected. PK was only collected in the dose escalation phase. PK was not collected for participants in the dose expansion arm.","reportingStatus":"POSTED","timeFrame":"Up to Day 5","title":"Pharmacokinetic Characteristics of Berzosertib","type":"SECONDARY","unitOfMeasure":"ratio"}